Vertex enters LOI with pan-Canadian Pharmaceutical Alliance for ALYFTREK
Vertex Pharmaceuticals signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, a new triple combination therapy for the treatment of cystic fibrosis in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane